From microLIQUID, we are pleased to invite you to join our booth #2325 at the 2019 AACC Clinical Lab Expo this August 6-8 in Anaheim, CA.
MicroLIQUID is a one-stop supplier of microfluidic solutions for Bioscience and Pharmaceutical companies. Starting with design and proof of concept, we work with our partners side-by-side from development, to New Product Introduction and mass-production of microfluidic devices, no matter what stage the project is in. Our experience is essential to establish the process of development of new technologies and their successful translation to automated microfluidic solutions.
At microLIQUID, our engineers and scientists have an extensive background and ample qualifications in the development and manufacture of immunoassays and molecular diagnostics platforms such as microarrays, a wide range of biosensors, PCR/RT-PCR and sample preparation applications, liquid biopsy etc. We can guide you in the process of Bio-translation from the bench to the market.
We would like to make the most of this event by arranging a meeting with you in order to talk about our common interests and demonstrate our latest offerings and technologies to you in depth as microLIQUID has grown over the last year.
Many thanks for your time, we look forward to hearing from you.
For more information: www.microLIQUID.
The translation of a bioassay to a microfluidic cartridge, with the objective of automating a bioassay, is a complex process that requires knowledge and expertise in both biology and engineering when it comes to product development. Understanding each step of the bioassay and the ability to adequately develop a microfluidic chip for each type of bioassay is essential to create a diagnostic device that can be marketed successfully.
At microLIQUID, our combined team of engineers and scientists have an extensive background and wide experience in the development and mass manufacture of immunoassays and molecular diagnostics platforms such as microarrays, biosensors, PCR / RT-PCR and sample preparation applications, etc. We can assist you in the process of Bio-translation from the bench to the market.
microLIQUID bio laboratory has expert scientists and engineers who work side-by-side to transfer bioassays to fully automated microfluidic cartridges. From sandwich or competitive 96well plate ELISA to microarray protein, from real-time PCR to DNA microarray, from conventional PCR in tubes to PCR microfluidic device for DNA amplification.
We integrate reagents into the microfluidic cartridge. With this, we achieve that all the bioassay reagents can be stored in the microfluidic chip at different formats, optimizing the reagents consumption for diagnosis, and thus achieve the desired process without manipulating the sample during the whole process.
For more information: www.microLIQUID.com
COC & COP microfluidic cartridge
At microLIQUID we have 10 years of experience working side by side with our customers, manufacturing microfluidic products based on hard polymers such as COC (cyclic olephine copolymer) and COP (cyclic olephine polymer). Our state-of-the-art micro-manufacturing processes for these types of microfluidic cartridges are unique in the industry.
These medical-grade plastics are perfect for microfluidics, as they are outstanding performers in different life science applications: molecular diagnostics, immunoassays, NGS, cell culture and cell diagnostics. These highly biocompatible copolymers have exceptional optical properties, including high clarity and high light transmissivity, in addition to very low moisture absorption, very low permeability to water vapor, and good chemical resistance.
We apply different high-skill engineering processes to our in-house manufacture of COC and COP microfluidic devices, undertaking the complete workflow from initial concept to mass manufacturing. We often begin with prototype production for design validation in the proof-of-principle stage. We might then continue with small- to medium-size production runs in preparation for ultimate mass manufacturing. In the critical area of integration of post-processing techniques, we have extensive experience in bonding processes and polymer surface treatments in order to fine-tune surface properties for different purposes, such as wettability modification, cell adherence, improvement of microfluidic droplet formation or DNA/protein spotting.
Our manufacturing services include:
Our aim is always to achieve the results necessary to make the projects we develop with our customers a complete success!
Molecular diagnostics have improved the diagnosis and treatment of millions of patients worldwide allowing clinicians to diagnose patients earlier as well as providing better ongoing therapies.
At microLIQUID we develop fully automated sample preparation and molecular diagnostic systems based on microfluidics.
Non-microfluidic diagnostic instruments usually require an important quantity of costly reagents, long analysis time, established lab infrastructure and trained professionals to operate, which limits their availability for large-scale screening applications in developed countries and primary care in developing countries. There is a strong demand for robust, cost-effective, and simple-to-operate instruments for molecular diagnostics.
Microfluidics systems have many advantages, such as short analysis time, reduction in fabrication costs, and low sample/reagent consumption.
Besides, most current microfluidic diagnostic devices are designed to target a single disease, such as a given cancer or a variety of pathogens. The future of molecular diagnostics lies in highly multiplexed microfluidic devices that can screen for potentially hundreds of diseases simultaneously.
microLIQUID is committed with the development of diagnostic systems, having the experience and expertise to develop and manufacture fully automated sample preparation and molecular diagnostics systems.
microLIQUID – MICROFLUIDIC IMMUNOASSAY
The high sensitivity and specificity of immunoassays make them a powerful tool in molecular diagnostics. microLIQUID, has proven that microfluidics is making a change in the field of diagnostics.
The current immunoassay ‘gold standard’ ELISA, while proven to be highly robust and reliable, suffers from large sample requirements, long diffusion times, and hence, long incubation times moreover, it requires a specific enzyme-fluorophore complex that does not interfere with the reaction.
In recent years, microLIQUID has focused on combining the classic ELISA approach with microfluidic technologies. Such devices enable quantitative immunoassay results by integrating sensitive optical or electrochemical detection methods. The main advantages of a microfluidic immunoassay compared to conventional approaches are:
1. Increase throughout and reproducibility, with automatic microfluidic immunoassay system.
2. Lower consumption of samples and reagents.
3. Speed up the antibody-antigen binding reactions.
Summarizing, the combination of microfluidics and immunoassay technologies can detect biomarkers with faster assay time, reduced volumes of reagents, lower power requirements, and higher levels of integration and automation compared to traditional approaches.
microLIQUID will be pleasured to meet you at Compamed 2018 on November 12-15 in Düsseldorf. We will be at Hall 8a/F34.1.
OEM & ODM of Microfluidic Cartridges and Instruments, IVD & Bioscience and Cell Culture have been our main commitment areas over the last few years. With capabilities spanning the entire value chain, microLIQUID has become a one-stop provider of Bioscience solutions.
Starting with design and proof of concept, we work with our company partners from development to mass-production of potentially fully certified IVD or Pharma products.
We offer full solutions with capabilities to integrate different technologies in developments with a microfluidics core, becoming more than just a microfluidics company. Looking at our customers necessities, we have reinforced ourselves including a bioscience department, automated instrumentation and equipment, offering higher quality and faster services than the competence thanks to these resources.
We detected the need from the customer and we have evolved to offer the required complete service. Our OEM & ODM microfluidic cartridge technologies fit the demand for improving the efficiency of techniques applied in medical devices for diagnostics, drug delivery and drug discovery. Because of our focus in these sectors, we work on how our microfluidic technology could interface with and provide improvements for current workflows, assaying techniques etc.
At Compamed 2018, we would love to have an opportunity to demonstrate our latest offerings and technologies to you in depth as microLIQUID has grown over the last few months.
See you there!
World Osteoporosis Day takes place every year on October 20.
Because of the ageing of the society, osteoporosis (
Currently, osteoporosis is commonly known as a “silent killer” disease. Usually osteoporosis manifests itself in a drastic manner, i.e. through fracture of the osteoporotic bone in the affected individual. Until now little or no measures for prevention or early detection of this disease are taken, because no simple, yet sufficiently precise or sensitive tools for early detection of individuals at risk of osteoporosis are available, there is a need to develop a efficient rapid diagnostics test to detect the disease.
At microLIQUID we are proud to be able to help with our expertise in microfluidic IVD system development in this cause by being part of PoCOsteo. We are working hand in hand together with European leaders, both from academia and industry, to develop new POC applications by using the latest microfluidic technologies applied to diagnostics.
The overall objective of the currently proposed PoCOsteo project is a IVD Point-of-care development. Also, the clinical validation and preparation for commercialization of thePoint-of-Care tool for bone disease. The osteoporosis prevention, osteoporosis detection and osteoporosis treatment is our aim.
For another year, microLIQUID will be exhibiting at AACC 2018 (Annual Scientific Meeting & Clinical Lab Expo) which will take place at McCormick Place, Chicago, IL, USA (July 31-August 2).
On behalf of our company, if you are attending to the event, we want to take advantage to have a meeting with you in order to talk about our common interests.
See you soon!
microLIQUID has shown once again that it strives to develop new point-of-care platforms by using the latest technologies in microfluidics.
In this project, microLIQUID will be working together with European leaders, both from academia and industry, to develop new PoC applications.
We invite you to read the press release issued by Ghent University at the start of the project in October 2017.
“Ghent, Belgium – October 1, 2017 – Ghent University and its project partners today announced the launch of the PoCOsteo project. Together they will develop and validate a point-of-care in-office device for identifying individuals at high risk of osteoporosis and osteoporotic fracture. The project is supported by the European Union’s Horizon 2020 Framework Programme for Industrial leadership in nanotechnologies, advanced materials, biotechnology and advanced manufacturing and processing (H2020-NMBP). The overall goal of the project is the development, clinical validation and preparation for commercialisation of a point-of-care tool for bone disease (a.o. osteoporosis) prevention, detection and treatment.
Indeed, as a consequence of the ageing of the society, osteoporosis (literally “porous bone”) and its complications is becoming more and more prevalent, making the bone disease a health priority in many parts of the world. Usually osteoporosis manifests itself in a drastic manner, i.e. through fracture of the osteoporotic bone in the affected individual. This causes a serious burden for the patient and a high medical care cost for the society. Currently osteoporosis is commonly known as a “silent killer” disease. Up to 20% of patients die in the first year following a hip fracture, mostly due to pre-existing medical conditions. Less than half of those who survive the hip fracture regain their previous level of function1. Early detection of individuals at risk of osteoporosis and starting a suitable treatment before fractures and complications arise would drastically improve the current situation. Until now little or no measures for prevention or early detection of osteoporosis are taken, because no simple, yet sufficiently accurate or sensitive tools for early detection are available.
The PoCOsteo system will employ electrochemical detection and brings together proteomics, genomics and microfluidics technologies. The in-office test will provide the results in real-time during consultation and can be performed by unskilled technicians even at rural areas where access to current state-of-the-art equipment is limited. The design will limit the amount of both expensive reagents and blood samples needed for the tests and so it not only reduces the cost of each test, which is of great importance, especially nowadays when full reimbursement is not practiced in many countries, but also reduces the patient’s pain and discomfort.
The project will be supported and advised by the IOF, the International Osteoporosis Foundation, which is the main global alliance of patient societies, research organizations, healthcare professionals and international companies working to promote bone, muscle and joint health.
Over the next four years, PoCOsteo will be coordinated by Ghent University. Industrial, academic and clinical partners will bring their expertise to the project: Universitat Rovira I Virgili and microLIQUID (Spain), Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung (Germany), Labman Automation (United Kingdom), Medizinische Universität Graz (Austria), Endocrinology and Metabolism Research Institute (Iran) and Fundico (Belgium).”